PET CT in the diagnosis and prognosis of osteosarcoma

Zhang, Xiaojuan; Guan, Zhe

doi:10.2741/4696

Cited by 37 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been many studies on the prognosis of osteosarcoma. Clinically, a set of PET/CT indicators can provide valuable information for the prognosis of patients with osteosarcoma, and serum miRNA can be used as a biomarker for the prognosis of osteosarcoma [ 33 , 34 ]. Moreover, many immune-related genes are associated with the prognosis of osteosarcoma in the study of immune microenvironment and tumor microenvironment [ 35 – 39 ].…”

Section: Discussionmentioning

confidence: 99%

Selection of lncRNAs That Influence the Prognosis of Osteosarcoma Based on Copy Number Variation Data

Zhang

Huang

Zhu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignancy in the musculoskeletal system. It is reported that copy number variation- (CNV-) derived lncRNAs contribute to the progression of osteosarcoma. However, whether CNV-derived lncRNAs affect the prognosis of osteosarcoma remains unclear. Here, we obtained osteosarcoma-related CNV data and gene expression profiles from The Cancer Genome Atlas (TCGA) database. CNV landscape analysis indicated that copy number amplification of lncRNAs was more frequent than deletion in osteosarcoma samples. Thirty-four CNV-lncRNAs with DNA-CNV frequencies greater than 30% and their corresponding 294 mRNAs were identified. Gene Ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analyses revealed that these mRNAs were mainly enriched in olfaction, olfactory receptor activity, and olfactory transduction processes. Furthermore, we predicted that a total of 23 genes were cis-regulated by 16 CNV-lncRNAs, while 30 transcription factors (TFs) were trans-regulated by 5 CNV-lncRNAs. Through t -tests, univariate Cox regression analysis, and the least absolute shrinkage and selection operator (LASSO), we constructed a CNV-related risk model including 3 lncRNAs (AC129492.1, PSMB1, and AC037459.4). The Kaplan-Meier (K-M) curves indicated that patients with high-risk scores showed poor prognoses. The areas under the receiver operating characteristic (ROC) curves (AUC) for predicting 3-, 5-, and 7-year overall survival (OS) were greater than 0.7, showing a satisfactory predictive efficiency. Gene set enrichment analysis (GSEA) revealed that the prognostic signature was intimately linked to skeletal system development, immune regulation, and inflammatory response. Collectively, our study developed a novel 3-CNV-lncRNA prognostic signature that would provide theoretical guidance for the clinical prognostic management of osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Selection of lncRNAs That Influence the Prognosis of Osteosarcoma Based on Copy Number Variation Data

Zhang

Huang

Zhu

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…The survival rate of these patients has improved as a result of comprehensive management in the form of intensive chemotherapy and surgery [3] . However, the progress has dwindled despite modern therapy over the past three decades, the prognosis remains poor for most patients with recurrent osteosarcoma [4] , [5] , [6] , [7] . Therefore, accurate prognosis and efficient therapy are urgently needed to improve the treatment of recurrence in osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma

Zhang

Liu

Kong

2021

Journal of Bone Oncology

View full text Add to dashboard Cite

Highlights Nomograms were constructed to provide accurate and individualized survival prediction for recurrence in osteosarcoma patients. The current study provides novel potential of seven RNAs (LINC00957, METL1, CA9, B3GALT4, ALDH1A1, LAMB3 and ITGB4) candidate prognostic biomarkers for recurrence in osteosarcoma patients. LncRNA LINC00957 may regulated the recurrence of osteosarcoma by pathways in cancer.

show abstract

“…At present, surgery combined with adjuvant chemotherapy remains the mainstay treatment option for OSA. Although this strategy has improved OSA patients' 5-year survival to some extent, the survival is still extremely low, especially for those with metastatic and recurrent OSA, with a survival rate less than 20% [ 8 , 9 ]. In addition to distant metastasis, the prime reasons for an adverse prognosis are poor response to chemotherapy and drug resistance to chemotherapeutics [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

Sui

Lin

2023

Journal of Oncology

View full text Add to dashboard Cite

Objective. To investigate the efficacy of recombinant human endostatin (rh-Endo) plus neoadjuvant chemotherapy (NACT) for osteosarcoma (OSA) and its influence on serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9). Methods. The case data of 141 OSA patients presented to the North District, Xiangyang Central Hospital Affiliated to Hubei University of Arts and Sciences from January 2018 to June 2019, were analyzed retrospectively. Patients receiving NACT (methotrexate + ifosfamide + adriamycin) were assigned into the control group (CNG; n = 65), while those treated with rh-Endo plus NACT were included in the combination group (CMG; n = 76). The following aspects were compared: clinical efficacy, serum tumor markers, serum VEGF and MMP-9 contents, inflammatory factors, incidence of adverse reactions, limb function scores at 6 months of follow-up, and prognostic quality of life (QOL). Results. A statistically higher overall response rate (ORR) was determined in CMG versus CNG (84.2% vs. 64.6%, P < 0.05). The pretreatment serum bone alkaline phosphatase (BALP), insulin-like growth factor (IGF)-1, serum amyloid A (SAA), VEGF, MMP-9, C-reactive protein (CRP), tumor necrosis factor (TNF)-α, and interleukin (IL)-10 levels differed insignificantly between the two cohorts ( P > 0.05); while except IL-10 that showed increased expression in both cohorts and was comparatively higher in CMG, the other 8 parameters reduced in both cohorts after 2 weeks of drug withdrawal, and the reduction of each parameter was more significant in CMG ( P < 0.05). The total adverse reaction rate was 30.2% in CMG, which was higher than that of 36.9% in CNG, albeit without a statistical difference ( P > 0.05). An evidently higher 2-year survival rate was determined in CMG ( P < 0.05). Conclusions. rh-Endo plus NACT is more effective than NACT alone in the treatment of osteosarcoma, which can validly restore the balance of vascular endothelial cells, reduce inflammation, and is worth promoting in clinic.

show abstract

PET CT in the diagnosis and prognosis of osteosarcoma

Cited by 37 publications

References 50 publications

Selection of lncRNAs That Influence the Prognosis of Osteosarcoma Based on Copy Number Variation Data

Selection of lncRNAs That Influence the Prognosis of Osteosarcoma Based on Copy Number Variation Data

Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma

Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

Contact Info

Product

Resources

About